Clinical trials
ARDS (Moderate or Severe) clinical trials
Below are recruiting ards (moderate or severe) clinical trials, each written for real people, not researchers. We’re tracking 1,499 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06598943RecruitingPhase 2
Study of two new drugs for ulcerative colitis
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
Chandler, ArizonaAges 18–75 - NCT06682169RecruitingPhase 3
New pill for chronic graft-versus-host disease after other treatments fail
This trial tests a new pill called rovadicitinib for chronic GVHD that has not improved after 2 to 5 other treatments. It compares the new drug to one chosen by your doctor from a list of approved options.
Hefei, AnhuiAges 18–70 - NCT06707246Recruiting
Comparing secukinumab and tofacitinib for hidradenitis suppurativa
This trial tests two medications, secukinumab and tofacitinib, to see which works better for moderate to severe hidradenitis suppurativa (a skin condition causing painful bumps) in Chinese patients. The goal is to find a more effective treatment option.
Hangzhou, ZhejiangAges 18–75 - NCT06342440Recruiting
Early detection of colon cancer and advanced polyps
This study aims to find colorectal cancer and advanced polyps (adenomas) earlier by looking at blood samples. Researchers hope a simple blood test might one day help detect colon cancer before it spreads.
Monrovia, CaliforniaAges 18 years+ - NCT05987449RecruitingPhase 1/Phase 2
Study of NXT007 for severe or moderate hemophilia A
This trial tests a new medicine called NXT007 to see if it is safe and effective for people with severe or moderate hemophilia A, including those with inhibitors. It may help reduce bleeding episodes.
Sacramento, CaliforniaAges 2–59 - NCT05689151Recruiting
Abrocitinib for adult moderate to severe atopic eczema
This study tests how well abrocitinib (a prescription medicine) works for adults with moderate to severe atopic dermatitis (atopic eczema). You may join if you meet the study’s health and consent requirements and your doctor believes abrocitinib is an appropriate option for you.
Amiens, SommeAges 18 years+ - NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Lancaster, CaliforniaAges 18–85 - NCT06389136RecruitingPhase 3
Study of upadacitinib for eczema after dupilumab didn't work
This trial tests if a pill called upadacitinib (a JAK inhibitor) can help adults with moderate-to-severe atopic dermatitis (eczema) that didn't improve enough with dupilumab. You may be able to join if your eczema is still active despite using dupilumab for at least 4 months.
Birmingham, AlabamaAges 18–63 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Murrieta, CaliforniaAges 18–75 - NCT07219173RecruitingPhase 2
Study of brenipatide for uncontrolled moderate to severe asthma
This study tests an investigational drug called brenipatide for people with moderate to severe asthma that isn't well controlled by current medicines. The purpose is to see if it can reduce asthma attacks better than a placebo (inactive treatment).
Tempe, ArizonaAges 18–75 - NCT07582783Recruiting
Treatment Persistence with Guselkumab for Moderate-to-Severe Plaque Psoriasis
This study tracks how well patients stick with guselkumab, a biologic injection medication for moderate-to-severe plaque psoriasis. Researchers want to understand real-world treatment outcomes in Romania to help improve psoriasis care.
BârladAges 18 years+ - NCT06711146RecruitingEarly Phase 1
CAR-T cell therapy for moderate to severe lupus
This trial tests a new type of CAR-T cell therapy designed to target and calm overactive immune cells in people with moderate to severe lupus. It uses a special metabolic boost to make the cells more effective, and may help reduce lupus symptoms.
Hangzhou, ZhejiangAges 18 years+ - NCT06716814RecruitingPhase 3
Continuing efanesoctocog alfa after earlier trial
This study provides continued access to the clotting factor treatment efanesoctocog alfa for people who have already been getting it in a previous trial. It helps ensure you can keep using the medicine if it is working for you.
PlovdivAges 6 years+ - NCT06721962RecruitingPhase 1/Phase 2
Testing an experimental treatment for moderate to severe Crohn's disease
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Scottsdale, ArizonaAges 18–65 - NCT06745583RecruitingPhase 2
Testing an oral drug for brain inflammation in Alzheimer's
This study tests an experimental oral medication (EI-1071) to see if it can reduce brain inflammation in people with Alzheimer's disease. The goal is to learn if it is safe and might help slow cognitive decline.
TaipeiAges 50–85 - NCT06747260RecruitingEarly Phase 1
Breast milk through the nose for HIE
This trial tests whether giving fresh breast milk through the nose is safe and possible for newborns with HIE (a brain injury from oxygen loss at birth) who are already receiving cooling therapy. It may help protect the brain and reduce injury.
BudapestAges Up to 2 days - NCT06754891RecruitingPhase 1
A study of TQH3906 for moderate to severe inflammatory bowel disease
This trial tests a new medicine (TQH3906) for people with moderate to severe ulcerative colitis or Crohn's disease that hasn't improved with other treatments. The goal is to see if it can help control inflammation in the gut.
Bengbu, AnhuiAges 18–75 - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT06756490RecruitingPhase 1
Study of HY-2003 for double chin reduction
This study tests a new medicine called HY-2003 to reduce extra fat under the chin (double chin). It is for adults who have moderate to severe submental fat and want to see if injections can help.
Beijing, Beijing MunicipalityAges 18–65 - NCT06764706Recruiting
Risankizumab for moderate-to-severe ulcerative colitis
This study observes how well risankizumab works for people with moderate to severe ulcerative colitis who are already starting it as part of their regular care. It helps doctors learn more about the drug's real-world effects.
Heidelberg, Baden-WurttembergAges 18 years+ - NCT06765005RecruitingPhase 1/Phase 2
Study of MG-K10 for Teens with Moderate to Severe Eczema
This study tests a new injectable medication called MG-K10 for teens with moderate to severe eczema that hasn't been well controlled with creams. The goal is to see if it can safely reduce inflammation and improve skin symptoms.
Hangzhou, ZhejiangAges 12–18 - NCT06775860RecruitingPhase 3
Testing ICP-332 for moderate to severe eczema
This trial tests an oral medication called ICP-332 for adults with moderate to severe eczema (atopic dermatitis) who haven't gotten enough relief from topical creams. It aims to see if the drug can reduce skin inflammation and itching.
Hefei, AnhuiAges 18–75 - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+ - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60
Hear when a new ARDS (Moderate or Severe) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ards (moderate or severe)?
- Yes. Clin2 currently lists 1,499 recruiting ards (moderate or severe) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ards (moderate or severe) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ards (moderate or severe) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.